Gene: TEAD2

8463
ETF|TEAD-2|TEF-4|TEF4
TEA domain transcription factor 2
protein-coding
19q13.33
Ensembl:ENSG00000074219 MIM:601729 Vega:OTTHUMG00000183174 UniprotKB:Q15562
NC_000019.10
PubMed
0   ANCO-SNPs
ND
1   
2.354e-1 (AD)  1.881e-1 (ND)   (Frontal_Cortex)
5.021e-1 (AD)  5.409e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
A4GALT0.848
LTBR0.845
CASP40.835
VASP0.831
CLIC10.826
DRAM10.825
CD400.823
IFITM20.813
ANXA20.812
TGFB10.811

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPEF1-0.602
SLC7A4-0.594
MARCH4-0.578
ABCC12-0.572
TPBGL-0.563
KCNB2-0.562
NEUROD6-0.555
HAS1-0.55
DLK2-0.55
BCL11A-0.548

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of TEAD2 mRNA"21346803
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEAD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEAD2 mRNA"27188386
C006780bisphenol Abisphenol A results in decreased expression of TEAD2 mRNA26063408
C006780bisphenol Abisphenol A results in decreased expression of TEAD2 mRNA25181051
C584509C646 compoundC646 compound results in increased expression of TEAD2 mRNA26191083
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of TEAD2 mRNA20971185
D003471CuprizoneCuprizone results in increased expression of TEAD2 mRNA26577399
D003976DiazinonDiazinon results in increased methylation of TEAD2 gene22964155
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene results in increased expression of TEAD2 mRNA"22485181
C118739entinostatentinostat results in decreased expression of TEAD2 mRNA27188386
C540355fenamidonefenamidone results in increased expression of TEAD2 mRNA27029645
C544151jinfukangjinfukang results in increased expression of TEAD2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of TEAD2 mRNA26752646
D007854LeadLead affects the expression of TEAD2 mRNA28903495
D008070LipopolysaccharidesTEAD2 protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]21131441
D008070LipopolysaccharidesTEAD2 protein promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]21131441
D008070LipopolysaccharidesTEAD2 protein results in increased susceptibility to Lipopolysaccharides21131441
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of TEAD2 mRNA28001369
C028007nickel monoxidenickel monoxide results in decreased expression of TEAD2 mRNA19167457
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of TEAD2 mRNA20971185
D009966OrphenadrineOrphenadrine affects the expression of TEAD2 mRNA23665939
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TEAD2 mRNA"25510870
C006253pirinixic acidpirinixic acid results in increased expression of TEAD2 mRNA23811191
D011441PropylthiouracilPropylthiouracil results in increased expression of TEAD2 mRNA24780913
C513428pyrachlostrobinpyrachlostrobin results in increased expression of TEAD2 mRNA27029645
D012834SilverSilver results in increased expression of TEAD2 mRNA27131904
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of TEAD2 mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of TEAD2 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of TEAD2 mRNA21570461|2405805
D019284ThapsigarginThapsigargin results in decreased expression of TEAD2 mRNA22378314
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of TEAD2 mRNA29024780
D014415TunicamycinTunicamycin results in decreased expression of TEAD2 mRNA22378314
D014520UrethaneUrethane results in decreased expression of TEAD2 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEAD2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of TEAD2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of TEAD2 mRNA23179753|2493525
D014635Valproic AcidValproic Acid results in decreased expression of TEAD2 mRNA21427059
D014635Valproic AcidValproic Acid results in increased expression of TEAD2 mRNA21427059
C088658zoledronic acidzoledronic acid results in decreased expression of TEAD2 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001085RNA polymerase II transcription factor binding-IBA21873635  
GO:0001134transcription factor activity, transcription factor recruiting-IMP20368466  
GO:0001223transcription coactivator binding-IPI20368466  
GO:0003700DNA-binding transcription factor activity-IBA21873635  
GO:0003700DNA-binding transcription factor activity-IDA18579750  19324877  
GO:0003700DNA-binding transcription factor activity-NAS8702974  
GO:0003705transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding-IEA-  
GO:0005515protein binding-IPI18579750  19324877  20368466  25416956  25751139  
GO:0043565sequence-specific DNA binding-IBA21873635  
GO:0044212transcription regulatory region DNA binding-IBA21873635  
GO:0046982protein heterodimerization activity-IPI20368466  
GO:0097718disordered domain specific binding-IMP20368466  
GO ID GO Term Qualifier Evidence PubMed
GO:0001570vasculogenesis-IEA-  
GO:0001843neural tube closure-IEA-  
GO:0003143embryonic heart tube morphogenesis-IEA-  
GO:0006355regulation of transcription, DNA-templated-NAS8702974  
GO:0006367transcription initiation from RNA polymerase II promoter-TAS-  
GO:0030903notochord development-IEA-  
GO:0035329hippo signaling-IBA21873635  
GO:0035329hippo signaling-IDA18579750  19324877  
GO:0045893positive regulation of transcription, DNA-templated-IMP20368466  
GO:0045944positive regulation of transcription by RNA polymerase II-IBA21873635  
GO:0048339paraxial mesoderm development-IEA-  
GO:0048368lateral mesoderm development-IEA-  
GO:0048568embryonic organ development-IBA21873635  
GO:0060548negative regulation of cell death-IEA-  
GO:0065003protein-containing complex assembly-IMP20368466  
GO:0071300cellular response to retinoic acid-IEA-  
GO:2000736regulation of stem cell differentiation-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-NAS8702974  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005667transcription factor complex-IBA21873635  
GO:0005829cytosol-IDA-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0071149TEAD-2-YAP complex-IDA20368466  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-2032785YAP1- and WWTR1 (TAZ)-stimulated gene expressionTAS
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-8878159Transcriptional regulation by RUNX3TAS
R-HSA-8951671RUNX3 regulates YAP1-mediated transcriptionTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25754111YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells. (2015 Jun)Bora-Singhal NStem Cells